bit.bio Accelerates Global Access to Human Cells with New Pricing Model and Distribution Hub

Following a strong $50M funding round, portfolio company bit.bio is leveraging scale and operational efficiencies to significantly lower the price per vial across its ioCells™ portfolio, expanding access to high-quality human cells globally.

With a new European distribution hub reducing lead times and logistics costs, the company is making human-relevant models more accessible to researchers across academia, biotech, and pharma.

We’re excited to see bit.bio translating growth into real cost advantages that can accelerate discovery and adoption of next-generation research tools.

#TechBio #CellProgramming #Biomanufacturing #LifeSciences #DynamkCapital